C T Deshmukh
Department of Pediatrics, KEM Hospital, Mumbai, India
First Created: 12/21/2000  Last Updated: 05/07/2019

Asthma Management Guidelines

Various expert committees and global expert panels have reviewed scientific literature over the past many years and have recommended the stepwise management of asthma according to asthma severity. Nearly all the national asthma programs have been following these guidelines. This definite and practical approach has been used worldwide with both the patient and doctor satisfaction.

Among the few recommendations are:

  • Stepwise approach to using medications and early use of anti-inflammatory medication especially in persistent asthma to gain and maintain control of asthma.

  • Classifications of asthma severity linked to treatment alternatives.

  • Prevention of asthma and its risk factors by reducing exposures to environmental allergens and secondhand tobacco smoke helps in optimal asthma control and reducing the dose of medications.

  • Identifying specific allergens for each patient by detail history and allergy testing, and recommendations for reducing exposures to these allergens

  • Emphasis on teaching asthma self-management and prevention risk factors to patients

  • Treatment according to the patient’s cultural, ethnic and economic factors

  • Objective measurement to be recommended wherever possible (PEFR meter)

Assessing Asthma Severity

First step in the patient's stepwise therapy is to assess the patient's disease severity. This is done by evaluating the symptoms, history including financial history, current treatment/medications and the response, clinical examination, and when the possible objective measurement of lung function to establish a baseline and assess severity. It is recommended that spirometry, which measures lung function, be used in an initial diagnostic workup.

Classification of Asthma severity:
Severe persistent asthma - Step 4

  • Continuous complaints. Frequents acute attacks. Limited physical activity.

  • Frequent or daily night symptoms.

  • FEV1/PEFR <60% PEFR variability >30%

Moderate persistent asthma - Step 3

  • Daily complaints. Needs daily-inhaled beta 2 agonist. Gets acute attacks twice a week.

  • Nocturnal symptoms more than once a week.

  • FEV1/PEFR 60-80% PEFR variability >30%

Mild persistent asthma - Step 2

  • Complaints more than twice a week but less than once a day. Acute attacks affect daily activity.

  • Nocturnal symptoms more than twice a month.

  • FEV1/PEFR 80%, PEFR variability 20-30%

Mild intermittent asthma - Step 1

  • Complaints twice a week.

  • No complaints in the night. PEFR normal between attacks. Attacks short duration and less than twice a month.

  • FEV1/PEFR 80% PEFR variability <30%

Individual is assigned to the most severe grade in which any of the above parameters occurs. An individual’s classification may change over time. At any level, patients can have a mild, moderate, or severe exacerbation of asthma.

For patient management in the stepwise plan, asthma drugs are divided into two groups. This classification reflects how we use the medication, not what the mechanism of action is.

Asthma Medications

  1. Long term therapy or controller drugs (maintenance)
    • Inhaled and oral steroids
    • Cromolyn sodium and Nedocromil sodium
    • Leukotriene antagonist
    • Long-acting beta2 agonist (inhaled salmeterol or sustained-release salbutamol)
    • Methylxanthines sustained released

  2. Quick relief therapy or short-acting bronchodilators
    • Inhaled short-acting beta2 agonist (salbutamol, terbutaline)
    • Inhaled anticholinergics (ipratopium bromide)
    • Oral steroids

Depending on asthma severity the above medications are recommended alone or in combinations and varying dosages.

Stepwise therapy summary:
Step 1:

  • First intervention should be a ß2 agonist delivered promptly by an age-appropriate inhalation device. This is given repeatedly when needed. It is also the treatment of choice for prophylaxis of exercise-induced asthma.

  • An oral ß2 agonist syrup may be appropriate for infants and toddlers with trivial symptoms who have never required emergency care, in order to avoid the expense and bother of a nebulizer.

  • If sub responsiveness to beta-2 agonists is present, then high dose oral corticosteroids should be given and continued until the patient is symptom-free for 24 hours. This usually requires 5 to 10 days of therapy.

Step 2:

  • If a poor response or needs daily use of short-acting bronchodilators, one of these drugs given twice a day, can be started to prevent asthma exacerbations, depending on preference for inhaled or oral medication.

    • Inhaled low dose corticosteroids.
    • Slow-release theophylline
    • Inhaled cromolyn or nedocromil sodium.
    • Consider Leukotriene antagonists for older patients.

Most prefer low dose inhaled steroids. Cromolyn administered by a nebulizer solution may be an alternative for young children who cannot use a metered-dose inhaler, even with an assist device. However, this modality is more costly and time-consuming, requiring multiple daily treatments.

Step 3:

  • If symptoms are not controlled or daily short-acting bronchodilators are needed then two drugs may be required for proper control.

  • Try with a moderate dose of inhaled steroids first.

  • Add slow-release theophylline or inhaled salmeterol if no response.

  • Alternate-morning administration of shorter-acting oral corticosteroids such as prednisone, prednisolone, or methylprednisolone can be given as an alternative to inhaled corticosteroids for most patients who cannot or will not comply with inhaled corticosteroids.

  • One or two maintenance medications at a twice-daily schedule with judicious use of a pre-exercise beta-2 agonist and appropriate measures of intervention is generally sufficient for control of asthma.

Step 4:

  • Patients who are still not free from symptoms and need more than once a day short-acting bronchodilators need at least two drugs for the prevention of asthma.

  • High dose inhaled steroids are given.

  • And long-acting bronchodilator (inhaled or oral beta 2 agonist or theophylline)

  • And/or oral steroids

All patients requiring maintenance medication should, in general, be evaluated to determine the role of environmental factors involved in their symptoms. This evaluation involves a careful history and skin testing for specific IgE. This would be particularly relevant for patients requiring more than either theophylline or low-dose inhaled steroids for maintenance. Specific immunotherapy may be tried in severe asthma who need two drugs for control. Each visit special attention is taken to evaluate the compliance and method of delivery of drugs.

Initiation of therapy:

  • Better to start at a higher step than the patient’s severity and then step down.

  • Achieve rapid control of symptoms by short oral course of steroids.

  • Alternately one can start at a step consistent with the patient’s severity and step up if needed.

Maintenance therapy:

  • Start and maintain therapy as mentioned above with either single or combination therapy.

  • Regular patient follow up every 1-6 months to decide if changes are needed in stepwise therapy.

  • Before making any changes in stepwise therapy check the patient’s compliance and environmental control measures.

Intervention alone is sufficient for the treatment of those with intermittent asthma. However, patients with chronic diseases need maintenance medication in addition, to prevent their daily symptoms. Patients with seasonal allergic disease may require maintenance medication, but only seasonally, and patients with chronic disease may require seasonal increases in their maintenance medication during seasonal allergic exacerbations. Adding or increasing maintenance medication at the times when increased symptoms are anticipated avoids morbidity and decreases the likelihood that urgent care will be needed.

Treatment goals:

Although there is no cure for asthma at present, asthma stepwise treatment along with environmental control measures is designed to provide optimal control of asthma and simultaneously limiting the side effects of drugs. The following goals should be aimed at:

  1. Prevent symptoms including nocturnal symptoms and exercise-induced symptoms.

  2. Near normal pulmonary functions.

  3. Maintaining normal physical activity and sleep patterns.

  4. Try to eliminate exposure to allergens and triggers and hence reduce exacerbations.

  5. Reduce the need for emergency visits for acute exacerbations and hospitalization.

  6. Reduce the dosage and side effects of drugs.

  7. Use of inhaled beta-2 agonist

  8. Use of short courses of high dose daily oral corticosteroids <4 times yearly.

  9. Satisfaction of patients and relatives.

Common Drugs Used in Asthma

Maintenance drugs:

  • Recognition of the importance of inflammation in the pathogenesis has led to an early use of inhaled steroids and is considered the first line of therapy by most in persistent asthma.
  • Steroids exert multiple effects on the pathogenesis of inflammation which includes interference with arachidonic acid metabolism, synthesis of leukotrienes and prostaglandins, prevention of activation of inflammatory cells, and increased responsiveness of b2 receptors.
  • Systemic corticosteroids should be considered in the management of acute asthma when the patient does not respond readily to bronchodilators.
  • Early use of corticosteroids shortens the course of asthma, prevents relapses, and reduces the need for hospitalization. The early use of corticosteroids is of particular importance in patients who have a history consistent with fatality-prone asthma.
  • Intravenous corticosteroids may be lifesaving in the treatment of severe intractable asthma.
  • After episodes of severe intractable asthma, complete restoration of pulmonary function may require weeks of treatment. Therefore after such events, corticosteroids should be continued at least until symptoms are controlled and pulmonary function is restored.
  • Inhaled steroids are the primary drugs of choice for persistent asthma. Currently available inhaled preparations include Beclomethasone diproprionate, Budesonide, Fluticasone, flunisolide, and triamcinolone.
  • Benefits of inhaled steroids are seen after 2-4 weeks of therapy. Aim is to get a daily dose that controls asthma and then step down to minimum dose, which can maintain that control.
  • Moderate to severe asthmatic require high doses inhaled steroids along with inhaled long-acting bronchodilators or theophylline.
  • Because of the potential for significant side effects from the prolonged use of systemic corticosteroids (and possibly high-dose inhaled corticosteroids), the need for oral corticosteroids should be monitored by pulmonary function tests, and inadequate control with maximal use of other treatment approaches should be a prerequisite for the long-term administration of systemic corticosteroids.
  • Adverse effects on linear growth from inhaled steroids are dose-dependent. There is no evidence growth retardation occurs with the dose of inhaled steroids being less than 400 mg/day.
  • Use of spacers can reduce the dose and side effects and should be used in any patient taking moderate to high doses of steroids.
  • For interventional therapy prednisolone or such equivalent can be given in the dose between 1-2 mg/kg per day in 2-3 divided doses. Dosage should be continued until the patient is free from symptoms and signs of asthma. The average duration of therapy is 7 days. Dosage should be discontinued without tapering. Oral corticosteroids are as effective as parenteral unless they are not retained.

Doses of inhaled steroids

Drug Low dose (mcg/day) Medium dose (mcg/day) High dose (mcg g/day)
Beclamethasone dipropionate 200-400 400-600 600-800
Budesonide 200-400 400-600 600-800
Fluticasone 125-250 250-500 500-750

Cromolyn sodium and Nedocromil sodium

  • Cromolyn remains the safest drug in asthma.
  • It modulates mast cell mediator release and eosinophil recruitment. Cromolyn has the ability to attenuate both early and late-phase IgE-mediated reactions.
  • It is not effective in acute episodes and may not be useful below 1 year of age.
  • In mild persistent asthma under 5 years of age can be tried before low dose steroid therapy. Cromolyn can be effective in many patients, alone or in conjunction with bronchodilators, in preventing the symptoms of mild-to-moderate asthma.
  • Two inhalations of the standard metered dose inhaler 4 times daily is the recommended dose.
  • Maximum effect may take 1-2 months.
  • Cromolyn can be effective in preventing or diminishing exercise-induced asthma when given 15 to 30 minutes before exercise.
  • Available as inhalers, spinhaler capsules, and nebulizer solution.


  • For the treatment of acute severe asthma, theophylline is less effective than inhaled or injected B2-selective agonists.
  • Bronchodilator effect by: phosphodiesterase inhibition, intracellular calcium modulation and prostaglandin antagonism.
  • Maintenance therapy with theophylline is effective in reducing the frequency and severity of the symptoms of chronic asthma. It may be similar in effectiveness to cromolyn or b2-agonists. It is generally used along with low dose steroids or cromolyn sodium.
  • Sustained release preparations allow for effective control of nocturnal symptoms.
  • Dose varies with age and other factors, begin dose at 10 mg/kg per day in two divided doses. Final dosage is usually based on the peak serum concentration measurement obtained at steady state.
  • Patients with mild chronic asthma may be controlled at steady-state theophylline serum concentrations less than 10 ug/ml; patients with more severe disease may require concentrations greater than 10 ug/ml for effective control of symptoms.
  • The rate of theophylline metabolism varies greatly among patients and is influenced by numerous medical conditions and other drugs. The rate of theophylline metabolism is reduced, leading to increased serum levels, in such conditions as cardiac decompensation, respiratory failure, hepatic cirrhosis, sustained high fever, viral infections, hypothyroidism, and after administration of cimetidine, oral contraceptives, erythromycin, ciprofloxacin, and disulfiram. In contrast, factors such as cigarette or marijuana smoking, hyperthyroidism, rifampin, phenytoin, carbamazepine, and phenobarbital increase the rate of metabolism.
  • Oral slow-release formulations provide stable serum concentrations and increases patient compliance. However, the rate and extent of absorption vary between formulations, between individuals, and possibly in the same individual from time to time. Food ingestion may also affect the rate of absorption in different ways depending on the specific formulation.
    Do not:

  1. Increase the dose if it is already at the lower end of the range.
  2. Maintain any dose that is not tolerated
  3. Allow generic substitution

Leukotriene antagonists and inhibitors

  • First new class of anti-asthma drugs in more than 25 years.
  • They can either block leukotriene receptors (Zafirlukast, Montelukast) or inhibit enzyme 5 lipoxygenase (Zileuton).
  • They produce long-term bronchodilatation.
  • Main advantage is that they can be taken orally once or twice a day.
  • They may be used instead of steroids in children more than 5 years of age who have mild persistent asthma. They can also be used along with steroids to reduce the doses of steroids. Exact role in management is still evolving.
Long acting Inhaled beta 2 agonist

  • They are used as adjunct to inhaled steroids and other anti-inflammatory agents. Never to be used as single-drug therapy.
  • Can be used in nocturnal symptoms.
  • Not to be used for acute attacks.
  • Available as Rotacaps, Inhaler or diskhaler.
  • Given as 25 mg per dose twice a day.

Intervention drugs

Short acting beta2 agonist

  • Beta-agonist bronchodilators vary in their degree of selectivity from non-selective (eg. isoproterenol) to relatively beta-selective agonists (beta 2-agonists) (eg. Salbutamol or albuterol, terbutaline). It is preferable to use a selective beta 2-agonist because they have a longer duration of action and are less likely to produce cardiovascular side effects.
  • Inhaled beta 2-agonists are preferable to oral drugs the treatment of chronic asthma because the rapid onset of action, are generally more effective than other routes of administration, and infrequently produce adverse reactions. Inhaled beta 2-agonists are generally the safest and most effective treatment for acute asthma. In general, oral 2-agonists should not be administered for the treatment of acute severe asthma. They are available in inhaler, nebulizer solution and oral forms.
  • Inhaled beta 2-agonists may be more effective when administered on an as-needed basis rather than on a regular basis in the treatment of chronic asthma. If greater than eight inhalations per day (or approximately one canister per month) are needed, the addition of cromolyn, nedocromil, or inhaled corticosteroids should be considered.
  • The administration of beta 2-agonists in the treatment of acute or chronic asthma is not a substitute for the early use of anti-inflammatory drugs.
  • Spacers attached to inhaled b2-agonists improve drug delivery in patients who do not correctly use inhalers. Patients must be carefully instructed, often more than once, in the use of inhaled B2-agonists because a large percentage of patients fail to use inhaler devices correctly.
  • Inhaled Beta 2-agonists are generally considered the agent of choice for the prevention of exercise-induced asthma. It should be taken 15 to 30 minutes before exercise.
  • Tolerance to B2-agonists may develop after continued use of these drugs and can be associated with an unrecognized decrease in efficacy and delay in seeking medical attention. This may be reversible after the administration of corticosteroids,
  • Tremor and central nervous system effects are minimized by inhalation of B2-agonists, although hypokalemia and significant cardiovascular effects can occur when these drugs are administered by this route. Serious adverse effects from the administration of B2-agonists, when administered in recommended doses, are uncommon when given orally and extremely uncommon when administered by inhalation.
  • B2-agonists when administered by inhalation, can produce a sudden paradoxical increase in bronchospasm, which may be life-threatening in some asthmatic patients.

Inhaled anticholinergic agents

  • Drugs such as ipratropium, appear to be more effective when used to treat patients with chronic mild to moderate asthma.
  • Ipratropium, may be indicated in whom alternative agents have not been sufficiently effective, are inappropriate because of other medical conditions, or have produced unacceptable side effects.
  • Inhaled anticholinergic medication is not sufficiently effective to be used as a single agent in the treatment of acute severe asthma but may benefit when combined with a B-agonist or other primary therapeutic agent.

Other drugs:


  • Antihistamines can be safely used in most patients with asthma.
  • Based on their ability to block late-phase responses to allergen exposure, newer antihistamines may play a greater role in the future treatment of asthma.
  • There is a strong clinical impression that improvement of upper respiratory tract symptoms by antihistamines in patients who have concomitant allergic rhinitis and asthma may facilitate the treatment of lower respiratory tract symptoms.

Hydration and Pharmacomucolytic Agents

  • Adequate hydration is recommended for patients with asthma, but careful monitoring of fluid and electrolyte balance should prevent overhydration. Dehydration may occur with severe asthma and should be corrected. However, fluid overload may have adverse pulmonary and circulatory effects and must be prevented by careful monitoring of fluid and electrolyte balance.
  • Guaifenesin and potassium iodide may be worth a trial in some asthmatic patients, although the mechanisms of action are unclear.


  • Infections associated with asthma exacerbations are almost always viral in origin and do not require antibiotic therapy.
  • Bacterial infections, such as acute and chronic sinusitis, should be treated appropriately, including the prompt and adequate use of antibiotics.
  • Influenza can be associated with increased asthma. Therefore appropriate immunization is essential in patients with moderately severe or severe asthma.


  • Routine vaccinations are not contraindicated in patients with asthma or other allergic conditions. Patients who have a history of egg sensitivity should be skin tested with the vaccination material.
  • Short-term, low-to-moderate dose systemic corticosteroids, alternate-day corticosteroids, or topical corticosteroids are not immunosuppressive and are not a contraindication for immunization.
  • Influenza vaccine and pneumococcal vaccine are recommended for patients with chronic pulmonary disease including asthma.

Drug delivery:

  • Where ever possible inhaled route of drug delivery is the preferred route in asthma except for theophylline.
  • Metered dose inhaler (MDI) can be used for a child who is about 6-7 years and is trained properly with the technique. It is better to use an assist device or spacer when using MDI for children.
  • Inhaled therapy with the metered-dose inhaler (MDI) has been effectively used for smaller children with the aid of a mask.
  • MDI with spacer should be the device of choice in children as it is a simple and convenient form of therapy and can be used in an acute exacerbation.
  • Children who are unable to take the medication with MDI or cannot tolerate it can be given the medication via the nebulizer.
  • Dry powder inhalers are other simple devices for use in children over 4-5 years of age.
Physicians and patients have several options to use the inhalation drugs in asthma and the device selected will depend on age, cost, and convenience of the patient.

Control of Precipitating Factors in Asthma

  • There is a strong link between inhaled allergens and asthma. Exposure to irritants or allergens, which the patient is sensitive to, increases the symptoms and precipitates asthma exacerbations.
  • It is very important to take a careful history to identify such factors. History is usually adequate for seasonal allergies.
  • If available, skin testing and in vitro testing for specific IgE antibodies may be useful to identify perennial indoor allergens.
  • Once asthma triggers have been identified the next step is to reduce the exposure to those triggers. Avoidance of triggers requires a high level of commitment on part of the patient and family.
  • Avoidance is most important in moderate to severe asthmatics and may help in reducing the dosage or need for medication. Aspects of responsibility for treatment may apply to all environments in which the child spends a significant amount of time, such as preschool, school, or daycare. The greatest effort is spent in relation to the bedroom, where children spend a major part of their time.

Recommendations (where ever possible):

  • Annual influenza vaccine for patients with persistent asthma.
  • Skin testing/in-vitro testing for at least in persistent asthma.
  • Not to use chemicals to kill house dust mites/cockroaches.
  • Aspirin not to be used in persons sensitive to it.
  • Avoid exposure to all tobacco smoke limiting exposure to allergens they are sensitive to, other irritants, as well as to house dust mite, cockroach, mold, animal, and pollen allergens.
  • Avoid exertion when air pollution levels are high.
  • Exercise-induced bronchospasm is common in children. Pretreatment with B2-agonists and/or cromolyn sodium can prevent symptoms. Optimal control of chronic asthma by anti-inflammatory therapy also can decrease the frequency and intensity of exercise-induced asthma.
  • Avoid taking nonselective b-adrenergic antagonists (blockers for migraine, stage fright)
  • Consider allergen immunotherapy when the connection between symptom and exposure to an unavoidable allergen is clear and symptoms occur during most of the year.
  • The use of acyclovir and/or varicella immune globulin should be considered in children who have a negative varicella history and/or antibody titer and who receive or recently have received systemic steroids and have been exposed to varicella.

Managing coexisting disease:

Asthma is better managed and drug therapy may be drastically reduced if coexisting diseases are managed. Examples of such diseases include rhinitis, sinusitis, Gastroesophageal reflux disease.

Assessment, monitoring, follow-up:

  • The condition of a patient's asthma will change depending on the environment, patient activities, management practices, and other factors. Thus, even when patients have their asthma under control, monitoring and treatment are needed to maintain control.
  • Consider signs, symptoms, pulmonary functions, quality of life, functional status, and history of asthma exacerbations, current drug therapy patient education, drug delivery techniques, and patient satisfaction. Home monitoring of PEFR is an important aspect of asthma treatment.
  • Patients should receive routine follow-up at scheduled intervals to assess control and assure the safety of the treatment.
  • Measurement of pre- and post-bronchodilator pulmonary function with office spirometry should be performed at each visit.
  • Growth and weight gain should be monitored because both asthma and treatment with maintenance inhaled or alternate-morning oral corticosteroids have the potential to slow growth.
  • Blood pressure measurement and eye exam for cataracts should be performed on all patients receiving maintenance corticosteroids. In susceptible patients, increased blood pressure may be a systemic effect of corticosteroids. Also, an increased risk of cataracts has been demonstrated even from inhaled corticosteroids.
  • Frequency of follow-up. Patients with an intermittent pattern of asthma can be followed with annual checkups if they meet the criteria for control. However, more frequent visits may be required to reinforce instructions.
  • Patients with a chronic pattern of asthma should be followed closely until criteria for control are met. Once disease control is achieved moderate to severe asthmatics should follow up every 3 months. Patients on low doses of inhaled corticosteroid or other single-maintenance medication may be followed once every 6 months.

Management of Acute Exacerbation of Asthma

Asthma exacerbations are acute episodes of progressive worsening of breathing, cough, wheeze, and chest tightness. These exacerbations are characterized by a decrease in PEFR which in turn can be easily quantified by PEFR meter or spirometer. These objective measurements indicate severity more accurately than symptoms.

The aim in the management of acute asthma is:

  1. Correct significant hypoxemia (O2, mechanical ventilation rarely needed)
  2. Reverse airflow obstruction as rapidly as possible.
  3. Reduce inflammation and the risk of recurrence by intensifying therapy.

Early treatment is important to prevent hospitalization and/or the attack from becoming severe. The following points are important for the same:

  1. Written instruction to the patient for self-treatment.
  2. Early diagnosis of worsening by PEFR meter or spirometer.
  3. Early contact with doctors regarding clinical or PEFR changes.
  4. Early increase in therapy (ß2 agonist, oral steroids).
  5. Remove precipitating factor if any.

Patients with high risk for asthma deaths need extra attention.

High risk factors for death in asthma:

  1. Past history of severe exacerbations.
  2. History of intubation mechanical ventilation for asthma.
  3. More than two hospitalizations for asthma in the past year.
  4. History admission to the Pediatric Intensive Care unit for asthma.
  5. Use of oral steroids for the current attack.
  6. Excessive use of b2 agonist.
  7. Frequent emergency visits for acute asthma.
  8. Associated cardio-respiratory diseases.


The diagnostic phase in a child with acute asthma should be short and comprise a brief history taking, inspection and auscultation of the thorax, transcutaneous oxygen measurement and, if possible, peak flow measurement (PEFR).

  • Patients should be treated immediately with oxygen, which should always be humidified.

  • Beta 2 agonists should be given immediately by inhalation if they are capable of effective inhalations or by injection if severely dyspneic. Frequent doses should be given and the duration and effect can be monitored by clinical assessment and PEFR measurement.

  • High dose corticosteroids should be administered promptly by mouth if there is no concern regarding retention, and parenterally if the patient is obtunded or vomiting.

  • Monitor clinical parameters, pulse oximetry, and PEFR. PEFR should be monitored every 30 minutes until the patient is out of danger.

  • Blood gases should be done if

    1. O2 saturation <94% at room air and patient dyspneic or

    2. O2 saturation <90% regardless of clinical findings.
After initial management one has to decide if patients need hospitalization or need to be sent home on medication.

Guidelines for admission:

Do not admit if:

  1. Comfortable at rest.
  2. No chest retractions.
  3. Not using accessory muscles of respiration.
  4. O2 saturation >90% in room air.

Admit if:

  • Labored respirations continue.
  • O2 saturation <90% in room air.
  • Dehydration, which requires intravenous fluids.
  • Past history of rapid deteriorations.
  • PEFR <50% or diurnal variation >25%.
  • Presence of complications such as subcutaneous emphysema and pneumothorax.

Do not keep patient for observation with simple measures for more than 3-4 hours, it is better to admit such patients for more intensive therapy and observation.

Treatment after admission:

  • Continue humidified oxygen monitoring pulse oximeter.

  • Continue inhaled ß2 agonist frequently depending on clinical and PEFR findings.

  • Intravenous fluids are needed in most with severe asthma as they are dehydrated due to - increased metabolism, increased insensible losses, decreased intake, vomiting. Dehydration can increase the viscosity of secretions, thereby increasing bronchiolar plugging and atelectasis. Overhydration can cause pulmonary edema. Hence correct the dehydration, then provide maintenance fluids, monitor fluid and electrolytes, and correct accordingly.


  • Inhaled ß2 agonist by nebulization either ½ hr to 1 hourly or continuous (continuous nebulization 0.1 to 0.3 mg/kg/hr to max 10-15 mg/hr).
  • Corticosteroids are the most important drugs in treating asthma

    • Can be given oral if patient can take PO steroid without emesis
    • Intravenous methyprednisolone 1-2 mg/kg/dose q6hrs, then depending on clinical course should be continued orally.
    • Inhaled therapy may be as effective as IV in acute therapy.
  • Anticholinergics: ipratropium bromide can be used and has additive effect to beta-agonists. Can be given as 250 mcg (1 cc) nebulization every 3-4 hourly.
  • Aminophylline drip may be useful by increasing diaphragm contractility, increasing mucociliary clearance, anti-inflammatory properties, and bronchodilatation, so it may be of some added benefit in patients with poor response to B-agonist.
  • Others routes of ß2 agonist

    • Subcutaneous epinephrine or terbutaline may also be given as an alternative. This route is selected if no other route is available/acceptable.
    • Salbutamol intravenous may be tried if minimal effect with inhalation therapy.
    • Intravenous continuous infusion (terbutaline, isoproterenol, albuterol) can be used when no improvement with inhaled bronchodilators. Terbutaline - bolus 10 mcg/kg over 30 min, infuse with 0.1 mcg/kg/min. Needs close monitoring of heart rate, cardiogram and oximeter
  • Other drugs:
    • Antibiotics: No role for routine use. May use if there is evidence of infection(sputum predominantly PMNs, sinus infection, pneumonia, suspicion of Mycoplasma or Chlamydia).
    • Magnesium SO4: Used as a bronchodilator. The mechanism is not clear but may be due to inhibition of Ca++ mediated smooth muscle contraction or direct inhibition of smooth muscle contraction. There are no controlled studies in children and has been tried IV in the dose of 30-70 mg/kg over 20-30 min. (max = 2 g).

Blood gases:

Hypoxemia in asthma is because of either V/P mismatch or respiratory failure and only pulse oximetry will not be able to differentiate the two, blood gases are important at this stage. Blood gases should be asked for when:

  • O2 saturation is less than 94% on room air and the patient is dyspneic.

  • or if O2 saturation <90% regardless of signs or symptoms.

  • Other investigations may be needed:
    • WBC - demarginated PMNs due to stress, steroids and infection.
    • Electrolytes -

      • hypokalemia due to beta 2 agonist
      • bicarbonate low due to metabolic acidosis
    • X-ray chest to look for complications.

Indications to transfer to PICU:

  1. Altered consciousness
  2. Exhaustion
  3. Sitting position accompanied by diaphoresis
  4. Severe decrease in air entry
  5. Monosyllable speech
  6. PCO2 rising, near normal, elevated,
  7. Pneumothorax, subcutaneous emphysema.
  8. Drug toxicity
  9. No improvement with standard therapy as above.
  10. Cardiac/respiratory arrest
  11. Metabolic acidosis
  12. PFT’s deteriorating despite treatment.

Indicators of impending respiratory failure:

  • Altered Level of Consciousness.
  • Monosyllable or not able to speak.
  • Markedly decreased or absent breath sounds
  • Cyanosis
  • Severe chest retractions and the use of accessory muscles.
  • Pulsus paradoxus >10 mmHg

Treatment in PICU:

  • Continue IV bronchodilators, continuous nebulizations, anticholinergics, steroids, and O2.

  • Treatment of acidosis: Acidosis is caused by hypoxemia, hypoperfusion, and respiratory failure. Acidosis leads to myocardial depression, decreased effectiveness of B-agonists, and ineffective rapid shallow breathing. Correct metabolic by giving bicarbonate (keep pH >7.20) 1 meq/kg.

  • Sedatives: May be given to prevent ineffective ventilation and interference with nebulization therapy. Preferably use those with broncho-dilating effect e.g. droperidol or ketamine. Use only in the PICU setting or when the patient on a ventilator.

Mechanical Ventilation - Indications:

  • Cardiorespiratory arrest
  • Severe altered mental status
  • Progressive exhaustion
  • Failure to respond to maximal medical treatment (acidotic, pCO2 >50 and rising, minimal chest movements, cyanosis, and hypoxemia).
  • Pneumomediastinum

Goals of ventilation:

  • Oxygenate and ventilate
  • Let the trapped air escape
  • Prevent barotrauma
  • Give rest to respiratory muscles
  • Give time for anti-inflammatory medications to work

Non-conventional interventions

  • CPAP/non-invasive positive pressure ventilation

  • Inhalation anesthetics

  • Bronchoscopy

  • Heliox

  • ECMO

  • NO
  • Patients may be discharged if they are comfortable at rest without retractions or use of accessory muscles of respiration and if O2 saturation is greater than 90% on room air. Early follow-up is important.

Out patient management summary

    Main areas: Treatment, education and follow-up

  • Treatment - Start or continue appropriate anti-inflammatory drugs (inhaled steroids). Use Bronchodilators when needed and also to prevent exercise-induced asthma. Change to MDI in the hospital before discharge. Treat exacerbating factors (GER, sinusitis, allergies).

  • Education - About signs and symptoms of asthma, what are the precipitating factors and how to detect and remove them, what to do if an attack occurs, the importance of follow-up regularly, and the use of PEFR meter.

1. National Asthma Education and Prevention Program, Expert Panel Report II. Guidelines for the diagnosis and management of asthma. NIH publication 97-4051, April, 1997.
2. Colasurdo GN, Larsen GL: Airway hyperresponsiveness. In: Busse W, Holgate S, eds. Asthma and Rhinitis. Boston, Blackwell Scientific Publications, Inc., 1994, pp 1044-1056.
3. Martinez FD, Wright AL, Taussig LM, et al: Asthma and wheezing in the first six years of life. N Engl J Med 332:133-138, 1995.
4. Sears MR, Rea HH, Fenwick J, et al: Deaths from asthma in New Zealand. Arch Dis Child 61:6-10, 1986.
5. Pedersen S, O'Byrne P: A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 52(suppl 39):1-34, 1997.
6. Drazen JM, Israel E, O'Byrne PM: Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 340:197-206, 1999.
7. Wenzel SE: New approaches to anti-inflammatory therapy for asthma. Am J Med 104:287-300, 1998.
8. Knorr B, Matz J, Bernstein JA, et al: Montelukast for chronic asthma in 6- to 14-year-old children. A randomized, double-blind trial. JAMA 279:1181-1186, 1998.
9. Kemp JP, Dockhorn RJ, Shapiro GG, et al: Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr 133:424-428, 1998.
10. de Jong VM, Janssens HM, Heijnen EMEW, et al: Spacer handling and variability of aerosol delivery in wheezy infants [Session A41]. ALA/ATS International Conference, San Diego, Ca, 1999.
11. Janssens HM, Heijnen EMEW, de Jong VM, et al: Variability of aerosol delivery via spacer devices in wheezy infants in daily life [Session A41]. ALA/ATS International Conference, San Diego, Ca, 1999.
12. Heijnen EMEW, Janssens HM, de Jong VM, et al: Spacers and electrostatic charge in daily life [Session A41]. ALA/ATS International Conference, San Diego, Ca, 1999.
13. Roorda RJ, Mezei G, Bisgaard H, et al: Response of pre-school children with asthma symptoms to inhaled fluticasone propionate: results from two multicenter studies [Session A41]. ALA/ATS International Conference, San Diego, Ca, 1999.
14. Mandelberg A, Tsehori S, Houri S, et al: Nebulized aerosol treatment in the pediatric emergency department — is it essential? Comparison with a metal spacer device for MDI [Session A41]. ALA/ATS International Conference, San Diego, Ca, 1999.
15. Lampl KL, Dixon SJ, Bonuccelli CM: Long-term safety and efficacy of zafirlukast (Accolate) in pediatric patients with mild-to-moderate asthma [Session A41]. ALA/ATS International Conference, San Diego, Ca, 1999.
16. British Asthma Guidelines Coordination Committee. British guidelines on asthma management: 1995 review and position statement. Thorax 1997; 52: S1-24.
17. Keeley D, Rees J. New guidelines on asthma management. Br Med J 1997 Feb 1; 314: 315-6.

Asthma Asthma 2019-05-07
Disclaimer: The information given by is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0